newsfilter
← Latest News
GlobeNewswire·

Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026

PMVP
  • PMV Pharmaceuticals announced updated Phase 2 results from the pivotal PYNNACLE clinical trial of rezatapopt will be presented at the 38th EORTC-NCI-AACR Symposium (ENA 2026).
  • The late-breaking oral presentation covers data from all PYNNACLE trial cohorts & focuses on efficacy, molecular activity, & safety in TP53 Y220C-positive advanced solid tumors.
  • The session is scheduled for November 20, 2026, at 15:00 CET in Barcelona, presented by Dr. Alison M. Schram from Memorial Sloan Kettering Cancer Center.
  • Rezatapopt (PC14586) is a first-in-class small molecule p53 reactivator designed to restore tumor-suppressor function in TP53 Y220C mutant proteins.
  • The U.S. FDA has granted Fast Track & Orphan Drug Designations for rezatapopt in specific indications including ovarian, fallopian tube, & primary peritoneal cancers.
  • The Phase 2 portion of the PYNNACLE trial is a registrational, single-arm expansion basket study across five cohorts involving approximately 70 sites.
  • The trial aims to evaluate rezatapopt efficacy at the recommended Phase 2 dose in patients with TP53 Y220C advanced solid tumors.
  • PMV Pharma is a precision oncology company headquartered in Princeton, New Jersey, with co-founder Dr. Arnold Levine establishing the field of p53 biology in 1979.
  • The press release includes forward-looking statements regarding future plans, trial success, & regulatory timelines subject to risks & uncertainties.